We are at the break of a large prospective study that will test our understanding of neoplastic transformation. There are obvious facts that the drop of the effect of hormones is followed by the reign of Cytokines which seems to coincide with a rise of cancers in the older population (above 50 years old). And now we have increasingly companies that propose genes to be screened for cancer predisposition (ie.GeneID, FDA approved).
Putting these facts together, it seems we are at the beginning of of a large prospective study that will monitor the changes in Cytokines against changes in selected genes and see what cancer will evolve over a 5-10 year period.
Cytokines tend to misbehave in the presence of certain genes (Fos, GSK, certain experiences-see related articles, G proteins -), these would play in the phosphorylation of unwanted genes. This component must be included in the observation.
One interesting aspect to point out is that while some researchers are focusing on gene alteration detection, others such as professor Zangh at UTEP are focusing on Antibodies created as a result of the neoplastic transformation. A recent rise in interest of lymphocytic (or activated lymphocytes) behavior in cancer may suggest the "a propos" of this last approach.
Monday, December 29, 2014
Wednesday, December 24, 2014
Tuesday, December 23, 2014
Options in Metastatic Her-2 positive Breast cancer
1.Pertuzumab + Herceptin + Taxanes
2.Adotrastuzumab EMTANSINE "a HER2-targeted antibody-drug conjugate (ADC) which contains the humanized anti-HER2 IgG1, trastuzumab, covalently linked to the microtubule inhibitory drug DM1 (a maytansine derivative) via the stable thioether linker MCC (4-[N-maleimidomethyl] cyclohexane-1-carboxylate). Emtansine refers to the MCC-DM1 complex." (DRUG)
3.LAPATINIB -XELODA
4."Data from five posters presented during the 2014 San Antonio Breast Cancer Symposium (SABCS) provide further evidence on the efficacy, safety and quality of life profile of eribulin, in the treatment of patients with locally advanced or metastatic breast cancer (MBC) and data in early stage breast cancer.
A second Phase 2, multicentre, open-label study, explores the feasibility of eribulin plus capecitabine as an adjuvant therapy in women with early-stage, estrogen receptor (ER) positive breast cancer." (drug)
2.Adotrastuzumab EMTANSINE "a HER2-targeted antibody-drug conjugate (ADC) which contains the humanized anti-HER2 IgG1, trastuzumab, covalently linked to the microtubule inhibitory drug DM1 (a maytansine derivative) via the stable thioether linker MCC (4-[N-maleimidomethyl] cyclohexane-1-carboxylate). Emtansine refers to the MCC-DM1 complex." (DRUG)
3.LAPATINIB -XELODA
4."Data from five posters presented during the 2014 San Antonio Breast Cancer Symposium (SABCS) provide further evidence on the efficacy, safety and quality of life profile of eribulin, in the treatment of patients with locally advanced or metastatic breast cancer (MBC) and data in early stage breast cancer.
A second Phase 2, multicentre, open-label study, explores the feasibility of eribulin plus capecitabine as an adjuvant therapy in women with early-stage, estrogen receptor (ER) positive breast cancer." (drug)
Friday, December 19, 2014
New drugs on the market
From Momenta:
"Necuparanib (formerly M402) is a novel, rationally designed, oncology drug candidate under investigation in metastatic pancreatic cancer. The use of heparins to treat venous thrombosis in cancer patients has generated numerous reports of antitumor activity; however, the dose of these products has been limited by their anticoagulant activity. Necuparanib, which is derived from unfractionated heparin, has been engineered to have significantly reduced anticoagulant activity while preserving the relevant antitumor properties of heparin. Necuparanib binds to multiple growth factors, adhesion molecules, and chemokines to inhibit tumor angiogenesis, progression, and metastasis."
JUST REMEMBER HEPARAN SURFACE IF THE COVER OF ESTROGEN RECEPTORS AND MANY OTHER RECEPTORS HUMMMM! CAN THIS PRODUCT WORK IN ER POSITIVE TUMOR?
" Twelve patients treated with necuparanib plus Abraxane and Gemzar completed the first 28-day treatment cycle. They had at least one follow up CT scan and were considered eligible for evaluating radiographic response. Out of them, seven patients showed a RECIST partial response and four patients reported stable disease.
Moreover, 11 out of the 12 patients showed a more than 50% decrease in CA19.9 levels (a predictive biomarker for long-term outcome and treatment response in pancreatic cancer) from baseline. The remaining patient achieved a more than 20% decrease from baseline. Overall, disease control was achieved in 92% of these 12 patients."
"Necuparanib (formerly M402) is a novel, rationally designed, oncology drug candidate under investigation in metastatic pancreatic cancer. The use of heparins to treat venous thrombosis in cancer patients has generated numerous reports of antitumor activity; however, the dose of these products has been limited by their anticoagulant activity. Necuparanib, which is derived from unfractionated heparin, has been engineered to have significantly reduced anticoagulant activity while preserving the relevant antitumor properties of heparin. Necuparanib binds to multiple growth factors, adhesion molecules, and chemokines to inhibit tumor angiogenesis, progression, and metastasis."
JUST REMEMBER HEPARAN SURFACE IF THE COVER OF ESTROGEN RECEPTORS AND MANY OTHER RECEPTORS HUMMMM! CAN THIS PRODUCT WORK IN ER POSITIVE TUMOR?
" Twelve patients treated with necuparanib plus Abraxane and Gemzar completed the first 28-day treatment cycle. They had at least one follow up CT scan and were considered eligible for evaluating radiographic response. Out of them, seven patients showed a RECIST partial response and four patients reported stable disease.
Moreover, 11 out of the 12 patients showed a more than 50% decrease in CA19.9 levels (a predictive biomarker for long-term outcome and treatment response in pancreatic cancer) from baseline. The remaining patient achieved a more than 20% decrease from baseline. Overall, disease control was achieved in 92% of these 12 patients."
Wednesday, December 10, 2014
Cytokines after age of 45
Now it is true that the Cytokines are able to induce cancers
the question is is it through the FAK gene or the BCAR3,TENC1
or directly through the MDM2,
or through pathways (ie. the LYN-CD22-SHP-1 pathway for lymphocyte )(wikipedia)whatever the connection, a number of amplification gene will be soon engaged to commit and amplify the process Myc, NPM1, Cyclin B1,
other supportive activities will be amplification of transcription factors
suppression of promoters of Tumor suppressor oncogenes
and some of the elongation genes (for telomeres)
disturbance of Mitochondrial genes and Ubiquitination genes
all these steps open an opportunity for a therapeutic intervention.
the way to treating cancer provide so many opportunities, soon we will be working at finding the best way to articulate and sequencing them!
the question is is it through the FAK gene or the BCAR3,TENC1
or directly through the MDM2,
or through pathways (ie. the LYN-CD22-SHP-1 pathway for lymphocyte )(wikipedia)whatever the connection, a number of amplification gene will be soon engaged to commit and amplify the process Myc, NPM1, Cyclin B1,
other supportive activities will be amplification of transcription factors
suppression of promoters of Tumor suppressor oncogenes
and some of the elongation genes (for telomeres)
disturbance of Mitochondrial genes and Ubiquitination genes
all these steps open an opportunity for a therapeutic intervention.
the way to treating cancer provide so many opportunities, soon we will be working at finding the best way to articulate and sequencing them!
Tuesday, December 2, 2014
New targeting Chemotherapies
Eribulin in Breast cancer
Tipiracil in Colon cancer
Ramucirumab and Paclitaxel (or FOLFOX) for Gastric cancer
Panobinostat for Myeloma
Pembrolizumab for lung cancers
Afatinib +chemotherapy for non small cell lung cancers that is EGFR with Mutation Del-19
Bortezomib +chemotherapy VR-CAP for Mantle cell
Nivolumab for Metastatic Renal cancer
anti-BRAF and Anti-MEK for Melanoma
Tipiracil in Colon cancer
Ramucirumab and Paclitaxel (or FOLFOX) for Gastric cancer
Panobinostat for Myeloma
Pembrolizumab for lung cancers
Afatinib +chemotherapy for non small cell lung cancers that is EGFR with Mutation Del-19
Bortezomib +chemotherapy VR-CAP for Mantle cell
Nivolumab for Metastatic Renal cancer
anti-BRAF and Anti-MEK for Melanoma
Subscribe to:
Posts (Atom)